AUS
NZ
UK
CA
USA
IND
Glanbia plc (-GLB), the Ireland-based global Better Nutrition company listed on Euronext Dublin, announced the repurchase of 17,885 ordinary shares on Wednesday, 15 July 2026, under its ongoing €50 million share buyback program. The shares were bought through the company’s appointed broker, J&E Davy, at prices between €23.30 and €23.52 per share, with a volume weighted average price of €23.4257. After settlement and cancellation, Glanbia will have 238,935,967 ordinary shares outstanding. This transaction is part of a buyback initiative launched on 25 February 2026 and scheduled to continue until 30 September 2026, a development investors in the nutrition and performance ingredients sector should monitor closely.
Key Points
- Glanbia plc (-GLB) is an Irish-headquartered global Better Nutrition company listed on Euronext Dublin (ISIN: IE0000669501)
- On 15 July 2026, the company repurchased 17,885 ordinary shares via broker J&E Davy, with all shares to be cancelled
- Share prices ranged from €23.30 to €23.52, with a volume weighted average price of €23.4257; the buyback program totals up to €50 million through 30 September 2026
- Investors should watch for ongoing daily buyback disclosures as Glanbia continues executing its €50 million program and track total shares cancelled relative to the program limit
Glanbia plc (-GLB) Completes 15 July 2026 Share Repurchase via J&E Davy on Euronext Dublin
Glanbia plc, known as the Better Nutrition company and trading under ticker -GLB on Euronext Dublin, confirmed on Thursday, 16 July 2026, that it repurchased 17,885 of its ordinary shares the previous day. The transactions were executed on Euronext Dublin through the company’s appointed broker, J&E Davy (intermediary code DAVYIE21), denominated in euros in line with Glanbia’s primary listing currency, and disclosed under the Market Abuse Regulation requirements.
The purchase consisted of two trades: 10,222 shares at €23.52 each at 08:04:05, and 7,663 shares at €23.30 each at 11:08:08, both on Euronext Dublin. These trades are detailed in the regulatory notice as required by Article 5(1)(b) of Regulation (EU) No 596/2014 (Market Abuse Regulation), with trade identifiers 00046747491TRLO1-1 and 00046749627TRLO1-1 respectively.
Details of Glanbia’s €50 Million Buyback Program: Timeline and Launch Date of 25 February 2026
The share repurchases reported on 16 July 2026 are part of a broader capital return strategy approved by Glanbia’s board. The €50 million buyback program was formally announced and commenced on 25 February 2026, with a scheduled end date of 30 September 2026, allowing approximately seven months for open market share repurchases. This structured buyback approach is common among European-listed companies aiming to return excess capital to shareholders while managing share count.
Buybacks under this program are typically executed in tranches, with daily purchases disclosed the following day per regulatory obligations. The cumulative value of shares repurchased to date was not aggregated in this announcement; investors seeking to monitor total spend against the €50 million limit should review all regulatory disclosures since 25 February 2026. Remaining buyback capacity was not specified in this release.
Share Price Range and Volume Weighted Average on 15 July 2026: €23.30 to €23.52
The disclosed pricing details provide insight into execution quality for the 15 July 2026 trades. The lowest price paid was €23.30 per share, the highest €23.52, reflecting an intraday spread of €0.22 across two trades. The volume weighted average price (VWAP) was €23.4257, a standard metric used by market participants and regulators to assess market-consistent buyback pricing.
The morning trade at 08:04:05 involved 10,222 shares at the session high of €23.52, while the later trade at 11:08:08 comprised 7,663 shares at €23.30. Using the VWAP, the total estimated expenditure for the day’s purchases was approximately €419,209. Glanbia did not explicitly state the daily total spend in the announcement.
Post-Settlement Share Count Reduction: Total Ordinary Shares at 238,935,967 After Cancellation
All shares repurchased under Glanbia’s buyback program are to be cancelled rather than held in treasury, directly reducing the total shares outstanding. This reduction increases earnings per share and other per-share metrics, assuming earnings remain constant. Following settlement and cancellation of the 17,885 shares acquired on 15 July 2026, Glanbia’s ordinary shares outstanding will be 238,935,967.
This cancellation permanently removes shares from the capital structure, enhancing shareholder value by lowering the denominator for dividends and earnings calculations. Investors should note this updated share count as a reference point. Glanbia’s ordinary shares carry ISIN IE0000669501, and the company’s LEI is 635400SRMCBHVMSKJS84.
Glanbia’s Business Overview: The Better Nutrition Company’s Global Reach and Sector Positioning
Glanbia plc positions itself as the Better Nutrition company, focusing on nutritional products and performance ingredients. Headquartered in Ireland and listed on Euronext Dublin, Glanbia operates internationally with a portfolio including performance nutrition brands, nutritional solutions for food and beverage manufacturers, and dairy-based ingredients. Its revenue streams combine branded consumer products and business-to-business ingredient supply, exposing the company to consumer trends and industrial food production volumes.
The global Better Nutrition sector benefits from long-term trends such as increased consumer protein awareness, growth in sports and active lifestyle nutrition, and rising demand for functional food ingredients. These dynamics support sustained demand for Glanbia’s products and underpin the company’s strategic investment case. The buyback program may signal management’s confidence in Glanbia’s financial strength and cash flow, though investors should assess all available information independently.
Regulatory Compliance: Market Abuse Regulation and Euronext Dublin Disclosure Obligations
Glanbia’s transaction disclosure complies with Article 5(1)(b) of Regulation (EU) No 596/2014 (Market Abuse Regulation), which mandates detailed reporting of share buyback trades, including venue, price, volume, and timing. This transparency ensures buybacks are conducted at market prices without manipulation or insider trading.
The announcement includes a detailed trade breakdown with timestamps, prices, and trade identifiers, enabling regulators and investors to verify compliance. Adhering to these disclosure requirements is essential for companies listed on regulated European exchanges. The immediate share price impact of this announcement was not evident from public information.
J&E Davy’s Role as Glanbia’s Broker for the Share Buyback Program
Glanbia appointed J&E Davy, a leading Irish stockbroking and investment banking firm, as the intermediary to execute share purchases under the buyback program. Operating under intermediary code DAVYIE21, J&E Davy conducts trades within parameters set by Glanbia’s board. Using an independent regulated broker is standard practice and helps protect against allegations of market manipulation under the Market Abuse Regulation.
This arrangement ensures that trade timing and pricing decisions are made by a regulated third party rather than company insiders, providing regulatory safeguards and operational consistency. Investor relations contacts include Liam Hennigan, Group Secretary and Head of Investor Relations (+353 86 046 8375), and Olivia Kennington, Deputy Group Secretary (+353 56 777 2200), for further program information.
Investor Impact: Share Cancellation Effects on Capital Structure and Earnings Per Share
For shareholders, ongoing share cancellations reduce total shares outstanding, increasing ownership stakes and earnings per share, assuming stable earnings. This form of capital return can be tax-efficient compared to dividends, though tax implications vary by investor jurisdiction.
Following the 15 July 2026 cancellation, Glanbia’s shares outstanding stand at 238,935,967. Investors should monitor this figure as further buybacks occur through the program’s September 2026 end date. The €50 million program represents a significant capital allocation relative to Glanbia’s market capitalization. The company did not disclose remaining buyback capacity or cumulative spend in this announcement; investors should consult all program disclosures for a full picture.
Risks Related to Glanbia’s Buyback and Euronext Dublin Listing
While buyback programs are generally shareholder-friendly, they carry company-specific risks. For Glanbia, allocating up to €50 million to share repurchases is a substantial use of cash. Should nutrition sector conditions worsen—due to input costs, consumer demand shifts, or currency fluctuations—the focus on buybacks over operational investment may attract scrutiny.
As a company listed on Euronext Dublin and subject to EU regulations including MAR, Glanbia must maintain timely and accurate disclosures. Failure to comply or perceptions of non-compliance could pose regulatory risks. Glanbia’s dual exposure to consumer nutrition brands and ingredient supply subjects it to competitive pressures from multiple fronts. The immediate share price effect of this announcement was not clear from public data.
Market Implications of Glanbia’s Ongoing Buyback Program Through September 2026
The continuation of Glanbia’s daily share repurchases since the 25 February 2026 program launch offers transparency that investors often view positively. Committing up to €50 million to repurchases suggests management believes shares are undervalued and that the company generates sufficient free cash flow to support buybacks without harming operations or strategy. However, this is an analytical inference, not explicit company guidance.
Investors will likely monitor the pace of program deployment and any announcements about extensions or changes. Daily purchase volumes may fluctuate based on market liquidity, share price, and board parameters. Further daily transaction disclosures are expected as the program proceeds toward its scheduled 30 September 2026 conclusion, with updates available through Glanbia’s investor relations.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. The information is based solely on a regulatory announcement by Glanbia plc and has not been independently verified. Past performance is not indicative of future results. Readers should seek independent financial advice before making investment decisions. Investment values and income can fall as well as rise, and investors may get back less than invested.
